Novartis Ag

Balzers Aktiengesellschaft

Artificial Sensing Instruments Asi Ag

Francois Legay

Peter Marbach

Rainer Hillenbrand

Jean-Michel Grenet

Severine Marrony

Judith Schaefer

Patrick Albientz

Yuan Gao

Helmut Rudigier

Kurt Tiefenthaler

Mara Fornaro

Alois Zetting

Roland Pfefferkorn

John Xu

Daniela Stoellner

Peter End

Veronique Briquet

High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Antibodies to modified human IGF-1/E peptides

A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.

Drug monitoring assay

Optical biosensor matrix

Growing community of inventors

Saint Louis, France

Francois Legay